Company:  89BIO, INC. (ETNB)
Form Type:  4
Filing Date:  3/25/2020 
CIK:  0001785173 
Address:  535 MISSION STREET
14TH FLOOR
 
City, State, Zip:  SAN FRANCISCO, California 94105 
Telephone:  (415) 500-4614 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$32.29  
Change: 
1.17 (3.76%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$531.33M
Trade ETNB now with 

© 2020  
Description of Business
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (" FGF21"), is currently being developed for the treatment of nonalcoholic steatohepatitis ("NASH"). NASH is a severe form of nonalcoholic fatty liver disease ("NAFLD"), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma ("HCC") and death. There are currently no approved products for the treatment of NASH. FGF21 is a clinically-validated mechanism that has been shown in humans to reduce steatosis and address cardio-metabolic dysregulation.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES